Close Menu

NEW YORK (GenomeWeb) – Illumina and China firm Boai NKY Medical Holdings have partnered to develop next-generation sequencing-based hereditary disease tests in China.

Under the agreement announced on Tuesday, NKY and Illumina will develop an NGS system based on Illumina's MiniSeq system and NKY's library prep kits and analysis software to develop in vitro diagnostics for hereditary kidney disease. The goal is to develop a platform that will meet regulatory criteria of China's National Medical Products Administration.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar features a panel of industry stakeholders in cancer diagnostics, proficiency testing and clinical care who will discuss the promise and challenges of liquid biopsy technologies in disease diagnosis, monitoring, and patient care management.

Nov
10
Sponsored by
LGC

The COVID-19 pandemic created a paradigm shift in modern healthcare, where regulations, protocols, and mindsets had to be reworked in just a matter of months to keep up with the pace of the virus.